

## **Global Epigenomics Market Report and Forecast 2023-2031**

Market Report | 2023-05-05 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Epigenomics Market Report and Forecast 2023-2031

Global Epigenomics Market Outlook

The global epigenomics market value is anticipated to grow at a CAGR of 13.1% during the forecast period of 2023-2031.

#### **Epigenomics Introduction**

Epigenomics refers to the study of changes in gene expression caused by modifications to the DNA molecule itself, rather than changes in the DNA sequence. These modifications can be passed down through generations, and can also be influenced by environmental factors such as diet, toxins, and stress. Epigenomics is a rapidly growing field with the potential to revolutionize the diagnosis and treatment of many diseases.

The use of epigenomics in healthcare is still relatively new, but it has the potential to improve our understanding of disease mechanisms and lead to the development of more personalized and effective treatments. Epigenomic research is already being used to develop new cancer therapies and to identify biomarkers for disease diagnosis and prognosis.

As the field continues to grow, there is a growing interest in developing epigenetic therapies for a range of diseases, including cancer, autoimmune disorders, and neurological conditions. There is also a need for further development of epigenetic technologies and techniques to make them more accessible and cost-effective.

Overall, the field of epigenomics holds great promise for improving our understanding and treatment of many diseases, and is likely to continue to be an area of significant research and development in the coming years.

#### **Epigenomics Market Scenario**

Epigenomics is a field of science that studies the interactions between genes and the environment that can result in the activation or deactivation of genes, thereby influencing health and disease outcomes. Epigenomics involves the study of modifications to DNA and histone proteins that regulate gene expression, without altering the underlying genetic code. The use of epigenomic information is becoming increasingly important in understanding the development of diseases such as cancer, Alzheimer's disease, and diabetes, among others.

The global epigenomics market is expected to experience significant growth in the coming years, driven by factors such as increasing government funding for epigenomics research, rising prevalence of cancer and other chronic diseases, and growing

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

demand for personalized medicine. The market is also expected to benefit from advancements in epigenomic technologies, including next-generation sequencing, mass spectrometry, and bioinformatics tools.

North America is expected to hold the largest share of the global epigenomics market, followed by Europe and the Asia-Pacific region. Factors driving the growth of the epigenomics market in North America include the presence of major market players, increasing government funding for epigenomics research, and rising prevalence of chronic diseases such as cancer and diabetes. The Asia-Pacific region is expected to experience significant growth in the coming years, driven by increasing government initiatives to support research and development activities, growing healthcare infrastructure, and rising healthcare spending in the region.

#### Epigenomics Market Segmentations

##### Market Breakup by Technology

- Histone Methylation
- Large Non-Coding RNA
- MicroRNA Modification
- DNA Methylation
- Chromatin Structures
- Others

##### Market Breakup by Product Type

- Kits
- Reagents
- Enzymes
- Others

##### Market Breakup by Application

- Diagnostics
- Pharmaceuticals

##### Market Breakup by End User

- Hospitals and Clinics
- Pharmaceuticals and Biotechnology Company

##### Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

#### Key Trends in the Epigenomics Market

Some key trends in the Epigenomics market are:

- Rising demand for personalized medicine: The growing awareness about personalized medicine is driving the growth of the Epigenomics market. Epigenomics offers a wide range of applications in the field of personalized medicine such as early detection, diagnosis, prognosis, and treatment of diseases.
- Increasing prevalence of cancer and other chronic diseases: The increasing prevalence of cancer and other chronic diseases is driving the demand for Epigenomics technologies. Epigenetic modifications play a crucial role in the development and progression of cancer and other chronic diseases, making it a promising tool for diagnosis, prognosis, and treatment of these diseases.
- Technological advancements: The development of advanced technologies in Epigenomics such as next-generation sequencing, DNA methylation analysis, histone modification analysis, and ChIP sequencing is driving the growth of the market. These advanced technologies offer high accuracy, sensitivity, and specificity, making them an ideal tool for Epigenomics research.
- Government initiatives and funding: The governments of various countries are investing heavily in Epigenomics research and development, which is driving the growth of the market. For instance, the National Institutes of Health (NIH) has launched various programs and initiatives to promote Epigenomics research and development.

Growing collaborations and partnerships: The increasing collaborations and partnerships among key players in the market are driving the growth of the Epigenomics market. The collaborations and partnerships are aimed at developing new products and technologies, expanding the product portfolio, and increasing the market share of the companies.

#### Epigenomics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Epigenomics AG
- Illumina, Inc.
- Merck KGaA
- Zymo Research Corporation
- Agilent Technologies, Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Epigenomics Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Success Rate
- 5 Epigenomics Epidemiology Analysis
  - 5.1 Epidemiology Overview (2016-2031)
  - 5.2 North America Epigenomics Epidemiology (2016-2031)
  - 5.3 Europe Epigenomics Epidemiology (2016-2031)
  - 5.4 Asia-Pacific Epigenomics Epidemiology (2016-2031)
  - 5.5 Latin America Epigenomics Epidemiology (2016-2031)
  - 5.6 Middle East & Africa Epigenomics Epidemiology (2016-2031)
- 6 Global Epigenomics Market Overview
  - 6.1 Global Epigenomics Market Historical Value (2016-2022)
  - 6.2 Global Epigenomics Market Forecast Value (2023-2031)
- 7 Global Epigenomics Market Landscape
  - 7.1 Epigenomics: Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Epigenomics: Product Landscape
    - 7.2.1 Analysis by Technology
    - 7.2.2 Analysis by Product Type
    - 7.2.3 Analysis by Application
    - 7.2.4 Analysis by End User
- 8 Epigenomics Challenges and Unmet Needs
  - 8.1 Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10 Global Epigenomics Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis
- 11 Global Epigenomics Market Segmentation
  - 11.1 Global Epigenomics Market by Technology
    - 11.1.1 Market Overview
    - 11.1.2 Histone Methylation
    - 11.1.3 Large Non-Coding RNA
    - 11.1.4 MicroRNA Modification
    - 11.1.5 DNA Methylation
    - 11.1.6 Chromatin Structures
    - 11.1.7 Others
  - 11.2 Global Epigenomics Market by Product Type
    - 11.2.1 Market Overview
    - 11.2.2 Kits
    - 11.2.3 Reagents
    - 11.2.4 Enzymes
    - 11.2.5 Others
  - 11.3 Global Epigenomics Market by Application
    - 11.3.1 Market Overview
    - 11.3.2 Diagnostics
    - 11.3.3 Pharmaceuticals
  - 11.4 Global Epigenomics Market by End User
    - 11.4.1 Market Overview
    - 11.4.2 Hospitals and Clinics
    - 11.4.3 Pharmaceuticals and Biotechnology Companies
    - 11.4.4 Academic and Research Institutes
    - 11.4.5 Others
  - 11.5 Global Epigenomics Market by Region
    - 11.5.1 Market Overview
    - 11.5.2 North America
    - 11.5.3 Europe
    - 11.5.4 Asia Pacific
    - 11.5.5 Latin America
    - 11.5.6 Middle East and Africa
- 12 North America Epigenomics Market
  - 12.1 Market Share by Country
  - 12.2 United States of America
  - 12.3 Canada
- 13 Europe Epigenomics Market
  - 13.1 Market Share by Country
  - 13.2 United Kingdom

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.3 Germany
- 13.4 France
- 13.5 Italy
- 13.6 Others
- 14 Asia Pacific Epigenomics Market
  - 14.1 Market Share by Country
  - 14.2 China
  - 14.3 Japan
  - 14.4 India
  - 14.5 ASEAN
  - 14.6 Australia
  - 14.7 Others
- 15 Latin America Epigenomics Market
  - 15.1 Market Share by Country
  - 15.2 Brazil
  - 15.3 Argentina
  - 15.4 Mexico
  - 15.5 Others
- 16 Middle East and Africa Epigenomics Market
  - 16.1 Market Share by Country
  - 16.2 Saudi Arabia
  - 16.3 United Arab Emirates
  - 16.4 Nigeria
  - 16.5 South Africa
  - 16.6 Others
- 17 Regulatory Framework
  - 17.1 Regulatory Overview
    - 17.1.1 US FDA
    - 17.1.2 EU EMA
    - 17.1.3 INDIA CDSCO
    - 17.1.4 JAPAN PMDA
    - 17.1.5 Others
- 18 Patent Analysis
  - 18.1 Analysis by Type of Patent
  - 18.2 Analysis by Publication year
  - 18.3 Analysis by Issuing Authority
  - 18.4 Analysis by Patent Age
  - 18.5 Analysis by CPC Analysis
  - 18.6 Analysis by Patent Valuation
  - 18.7 Analysis by Key Players
- 19 Grants Analysis
  - 19.1 Analysis by year
  - 19.2 Analysis by Amount Awarded
  - 19.3 Analysis by Issuing Authority
  - 19.4 Analysis by Grant Application
  - 19.5 Analysis by Funding Institute
  - 19.6 Analysis by NIH Departments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
  - 20.1 Analysis by Trial Registration Year
  - 20.2 Analysis by Trial Status
  - 20.3 Analysis by Trial Phase
  - 20.4 Analysis by Therapeutic Area
  - 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
  - 21.1 Analysis by Funding Instances
  - 21.2 Analysis by Type of Funding
  - 21.3 Analysis by Funding Amount
  - 21.4 Analysis by Leading Players
  - 21.5 Analysis by Leading Investors
  - 21.6 Analysis by Geography
- 22 Partnership and Collaborations Analysis
  - 22.1 Analysis by Partnership Instances
  - 22.2 Analysis by Type of Partnership
  - 22.3 Analysis by Leading Players
  - 22.4 Analysis by Geography
- 23 Supplier Landscape
  - 23.1 Epigenomics AG
    - 23.1.1 Financial Analysis
    - 23.1.2 Product Portfolio
    - 23.1.3 Demographic Reach and Achievements
    - 23.1.4 Mergers and Acquisitions
    - 23.1.5 Certifications
  - 23.2 Illumina, Inc.
    - 23.2.1 Financial Analysis
    - 23.2.2 Product Portfolio
    - 23.2.3 Demographic Reach and Achievements
    - 23.2.4 Mergers and Acquisitions
    - 23.2.5 Certifications
  - 23.3 Merck KGaA
    - 23.3.1 Financial Analysis
    - 23.3.2 Product Portfolio
    - 23.3.3 Demographic Reach and Achievements
    - 23.3.4 Mergers and Acquisitions
    - 23.3.5 Certifications
  - 23.4 Zymo Research Corporation
    - 23.4.1 Financial Analysis
    - 23.4.2 Product Portfolio
    - 23.4.3 Demographic Reach and Achievements
    - 23.4.4 Mergers and Acquisitions
    - 23.4.5 Certifications
  - 23.5 Agilent Technologies, Inc.
    - 23.5.1 Financial Analysis
    - 23.5.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 23.5.3 Demographic Reach and Achievements
  - 23.5.4 Mergers and Acquisitions
  - 23.5.5 Certifications
- 24 Epigenomics - Distribution Model (Additional Insight)
  - 24.1 Overview
  - 24.2 Potential Distributors
  - 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
  - 26.1 Very Small Companies
  - 26.2 Small Companies
  - 26.3 Mid-Sized Companies
  - 26.4 Large Companies
  - 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
  - 27.1 Government Funded
  - 27.2 Private Insurance
  - 27.3 Out-of-Pocket



## Global Epigenomics Market Report and Forecast 2023-2031

Market Report | 2023-05-05 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com